Managed Healthcare Exceutive » Biosimilars
4 FOLLOWERS
Check out our blog for biosimilar articles. Managed Healthcare Executive is the leading resource for payer decision-makers. We provide industry news, market trends, and peer-inspired insights about improving outcomes, enhancing the patient experience, and lowering the cost of care.
Managed Healthcare Exceutive » Biosimilars
6M ago
The review focused on Remicade (infliximab) and Enbrel (etanercept). The annualized discontinuation rate was 21% among patients who had undergone nonmedical switching to biosimilars. However, the rates were similar to those found in some separate analyses of patients on reference biologics ..read more
Managed Healthcare Exceutive » Biosimilars
6M ago
Tom Newcomer, head of U.S. market access for Samsung Bioepis, maker of Hadlima, a Humira biosimilar, said some potential customers want to see which biosimilars will grab a large market share before deciding on which one to buy ..read more
Managed Healthcare Exceutive » Biosimilars
6M ago
Study-based findings provide support for considerable implications of multiple switching between biosimilar and originator products ..read more
Managed Healthcare Exceutive » Biosimilars
6M ago
The question of whether it is safe to switch among biosimilars, not just between biosimilars and the reference product, is coming more pertinent as the number of biosimilars on the market increases ..read more
Managed Healthcare Exceutive » Biosimilars
6M ago
A phase 3 trial sponsored by the biosimilar maker shows that its candidate, temporarily named MYL-1601D, has the same immunogenicity, efficacy and safety levels as NovoLog, Novo Nordisk’s brand-name insulin aspart. Novolog and its authorized generic currently have the U.S. insulin aspart market to themselves ..read more
Managed Healthcare Exceutive » Biosimilars
6M ago
OptumRx will offer Amjevita and two other biosimilars alongside Humira. OptumRx is the first large PBM to make public its plans for the seven Humira biosimilars that may come on the market next year ..read more
Managed Healthcare Exceutive » Biosimilars
10M ago
Amgen’s Amjevita was already on the pharmacy benefit manager’s National Preferred Flex Formulary ..read more
Managed Healthcare Exceutive » Biosimilars
10M ago
Boehringer Ingelheim is pricing its biosimilar 5% to 7% below AbbVie’s top selling drug ..read more
Managed Healthcare Exceutive » Biosimilars
10M ago
7 of them launched during the first several days of July, joining Amgen's Amjevita in the suddenly crowded market of Humira competitors. Pfizer’s Abrilada is the only FDA-approved Humira biosimilar that hasn’t launched ..read more
Managed Healthcare Exceutive » Biosimilars
1y ago
Cuban, of "Shark Tank' fame and owner of the Dallas Mavericks, called drugs prices ‘insane’ and used some profanity when talking pharmacy benefit managers at the annual meeting of the Association for Accessible Medicines yesterday. Cuban has co-founded an online pharmacy that he says will make drug prices lower and transparent ..read more